Almirall, S.A. (BME:ALM)
Spain · Delayed Price · Currency is EUR 10.68
+0.04 (0.38%)
Jul 17, 2026, 5:35 PM CET
Almirall Revenue
In the year 2025, Almirall had annual revenue of 1.11B EUR with 12.51% growth. Almirall had revenue of 275.58M in the quarter ending December 31, 2025, with 12.36% growth.
Revenue
1.11B
Revenue Growth
+12.51%
P/S Ratio
2.08
Revenue / Employee
531.70K
Employees
2,108
Market Cap
2.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 123.90M | 12.51% |
| Dec 31, 2024 | 990.63M | 91.84M | 10.22% |
| Dec 31, 2023 | 898.79M | 20.28M | 2.31% |
| Dec 31, 2022 | 878.51M | 42.01M | 5.02% |
| Dec 31, 2021 | 836.50M | 22.01M | 2.70% |
| Dec 31, 2020 | 814.49M | -96.17M | -10.56% |
| Dec 31, 2019 | 910.66M | -711.34M | -43.86% |
| Dec 31, 2018 | 1.62B | 866.22M | 114.61% |
| Dec 31, 2017 | 755.79M | -103.43M | -12.04% |
| Dec 31, 2016 | 859.22M | 90.22M | 11.73% |
| Dec 31, 2015 | 769.00M | -638.45M | -45.36% |
| Dec 31, 2014 | 1.41B | -243.55M | -14.75% |
| Dec 31, 2013 | 1.65B | -149.40M | -8.30% |
| Dec 31, 2012 | 1.80B | 927.32M | 106.21% |
| Dec 31, 2011 | 873.08M | -129.01M | -12.87% |
| Dec 31, 2010 | 1.00B | -33.18M | -3.20% |
| Dec 31, 2009 | 1.04B | -21.67M | -2.05% |
| Dec 31, 2008 | 1.06B | 139.54M | 15.21% |
| Dec 31, 2007 | 917.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.44B |
| Laboratorios Farmaceuticos Rovi | 741.09M |
| Faes Farma | 674.06M |
| Laboratorio Reig Jofre | 335.01M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 251.89M |
| Pharma Mar | 225.43M |
| Atrys Health | 144.31M |
Almirall News
- 2 months ago - Almirall Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Almirall Slides: Q1 2026 - Filings
- 2 months ago - Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business - Business Wire
- 3 months ago - Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology - Business Wire
- 4 months ago - Almirall presents long-term interim results from Phase 3b ADlong study - TheFly
- 4 months ago - Almirall presents clinical, real-word data across portfolio at AAD meeting - TheFly
- 4 months ago - AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne - Business Wire
- 4 months ago - Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology - Business Wire